2019 Fiscal Year Final Research Report
Development of therapeutic drugs targeting VGF-modifying peptides in retinal diseases
| Project/Area Number |
17K11486
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Gifu Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
原 英彰 岐阜薬科大学, 薬学部, 教授 (20381717)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Keywords | 網膜神経節細胞 / 緑内障 |
|---|
| Outline of Final Research Achievements |
In this study, to clarify the effects of VGF nerve growth factor inducible (VGF), a secreted neuropeptide, on retinal ganglion cells, we examined the effects of VGF peptides using mouse optic nerve crush model and cultured rat retinal ganglion cells. As a result, we found that AQEE30 has 1) a protective effect on retinal ganglion cell death after optic nerve crush in mice, and 2) promoting effects on survival of retinal ganglion cells and neurite outgrowth in rat cultured retinal ganglion cells. In addition, known and novel shorter VGF-derived peptides were investigated, and some VGF-derived peptides were more effective in promoting neurite outgrowth than a combination of brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF).
|
| Free Research Field |
薬理学
|
| Academic Significance and Societal Importance of the Research Achievements |
新規VGFペプチドが緑内障をはじめとした網膜疾患治療薬として応用することを目的としている。これらの課題を解決することにより、直接的に網膜神経細胞を保護するような治療薬のない本領域において全く新しい画期的な治療法の開発に繋げることができるかもしれない。
|
